


<b>AMENDMENT TRANSMITTAL LETTER (Small Entity)</b> Applicant(s): Van Eyk et al.				Docket No. <b>PTQ-0058</b>	
Application No. <b>10/824,027</b>	Filing Date <b>April 14, 2004</b>	Examiner <b>Desai, Anand U</b>	Customer No. <b>26259</b>	Group Art Unit <b>1653</b>	Confirmation No. <b>6007</b>
Invention: <b>Methods and Compositions for Modulating Proteins Modified in Preconditioning Against Ischemia/Hypoxia</b>					
<b>COMMISSIONER FOR PATENTS:</b>  Transmitted herewith is an amendment in the above-identified application.  <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27  The fee has been calculated and is transmitted as shown below.					
<b>CLAIMS AS AMENDED</b>					
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	20 -	20 =	0	x \$25.00	\$0.00
INDEP. CLAIMS	6 -	6 =	0	x \$100.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
<b>TOTAL ADDITIONAL FEE FOR THIS AMENDMENT</b>					<b>\$0.00</b>
<input checked="" type="checkbox"/> No additional fee is required for amendment. <input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ <input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. <b>5-1619</b> <input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17. <input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached. <b>WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</b>					
 Kathleen A. Tyrrell, Reg. No. 38,350  Licata & Tyrrell P.C. 66 East Main Street Marlton, New Jersey 08053 Tel: 856-810-1515 Fax: 856-810-1454			Dated: <b>February 11, 2005</b>  <div style="border: 1px solid black; padding: 5px;">         I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on           _____          (Date)           _____          Signature of Person Mailing Correspondence           _____          Typed or Printed Name of Person Mailing Correspondence       </div>		
CC:					

2/14/05

1fw



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: PTQ-0058

Inventors: Van Eyk et al.

Serial No.: 10/824,027

Filing Date: April 14, 2004

Examiner: Desai, Anand U

Customer No.: 26259

Group Art Unit: 1653

Confirmation No.: 6007

Title: Methods and Compositions for  
Modulating Proteins Modified in  
Preconditioning Against  
Ischemia/Hypoxia

"Express Mail" Label No. EV583918287US  
Date of Deposit February 11, 2005

I hereby certify that this paper is being deposited  
with the United States Postal Service "Express Mail  
Post Office to Addressee" service under 37 CFR 1.10  
on the date indicated above and is addressed to the  
Mail Stop, Commissioner for Patents, P.O. Box 1450,  
Alexandria, VA 22313-1450.

By Kathleen A. Tyrrell  
Typed Name: Kathleen A. Tyrrell, Reg. No. 38,350

Mail Stop  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**Preliminary Amendment and Reply to Restriction Requirement**

This is a Preliminary Amendment and reply to the  
Restriction Requirement mailed January 11, 2005, setting a  
one (1) month statutory period for response. Please enter  
the following remarks into the record.

Attorney Docket No.: PTQ-0058  
Inventors: Van Eyk et al.  
Serial No.: 10/824,027  
Filing Date: April 14, 2004  
Page 2

**Amendments to the claims** are reflected in the listing of claims which begins on page 3 of this paper.

**Remarks/Arguments** begin on page 9.